{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:55:57Z","timestamp":1789433757852,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diagmicrobio.2025.116993","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:20:51Z","timestamp":1751664051000},"page":"116993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["In-vitro activity of cefepime\/enmetazobactam against extended spectrum beta-lactamases and\/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India"],"prefix":"10.1016","volume":"113","author":[{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiza","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devishree","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harathi","family":"Ragothaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniya","family":"KrishnaMoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvasri","family":"Manokaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthur","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth","family":"Nagvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Karthik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"Dwarakanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Todi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanalakshmi","family":"Solaimalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0001","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116993_bib0002","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116993_bib0003","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lef\u00e8vre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116993_bib0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jmii.2010.06.001","article-title":"Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study","volume":"44","author":"Chang","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116993_bib0005","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116993_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00298-22","article-title":"Cefepime\/enmetazobactam is a clinically effective combination targeting extended-spectrum \u03b2-lactamase-producing enterobacterales","volume":"66","author":"Shapiro","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0007","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem resistant gram negatives","author":"Bonnin","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","volume":"25","author":"Belley","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2024.04.014","article-title":"Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates","volume":"38","author":"Morrissey","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"13","key":"10.1016\/j.diagmicrobio.2025.116993_bib0010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116993_bib0011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13756-020-00856-w","article-title":"Prevalence and molecular characteristics of ESBL and AmpC \u03b2 -lactamase producing Enterobacteriaceae strains isolated from UTIs in Egypt","volume":"9","author":"Mohamed","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116993_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091800","article-title":"Detection of OXA-1 \u03b2-lactamase gene of Klebsiella pneumoniae from blood stream infections (BSI) by conventional PCR and in-silico analysis to understand the mechanism of OXA mediated resistance","volume":"9","author":"Sugumar","year":"2014","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.116993_bib0013","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1093\/jac\/dkaa181","article-title":"Detailed characterization of an IncFII plasmid carrying blaOXA-48 from Lebanon","volume":"75","author":"Moussa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0014","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0015","series-title":"Performance standards for antimicrobial testing","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0016","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoints for cefepime-enmetazobactam. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Cefepime-enmetazobactam_addendum_22_May_2024.pdf."},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0017","unstructured":"FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria. Cefepime and enmetazobactam injection. https:\/\/www.fda.gov\/drugs\/development-resources\/cefepime-and-enmetazobactam-injection."},{"key":"10.1016\/j.diagmicrobio.2025.116993_bib0018","series-title":"Clinical microbiology procedures handbook","doi-asserted-by":"crossref","DOI":"10.1128\/9781683670438.CMPH","article-title":"Synergism testing: broth microdilution checkerboard and broth macrodilution method","author":"Leber","year":"2016"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116993_bib0019","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116993_bib0020","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/cid\/ciac688","article-title":"Breaking down the breakpoints: rationale for the 2022 clinical and laboratory standards institute revised piperacillin-tazobactam breakpoints against enterobacterales","volume":"77","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116993_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01676-21","article-title":"Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing enterobacterales","volume":"66","author":"V\u00e1zquez-Ucha","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116993_bib0022","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.diagmicrobio.2013.10.008","article-title":"Resistance surveillance program report for selected European nations (2011)","volume":"78","author":"Jones","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116993_bib0023","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.13245","article-title":"Cefoperazone\/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: potential factors affecting the pharmacokinetic\/pharmacodynamic target attainment","volume":"125","author":"Dong","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116993_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00168-20","article-title":"Unorthodox parenteral \u03b2-lactam and \u03b2-lactamase inhibitor combinations: flouting antimicrobial stewardship and compromising patient care","volume":"64","author":"Palwe","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116993_bib0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","article-title":"Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program","volume":"47","author":"Ambrose","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116993_bib0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jinf.2006.09.004","article-title":"Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections","volume":"54","author":"Lee","year":"2007","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116993_bib0027","doi-asserted-by":"crossref","first-page":"e00078","DOI":"10.1128\/AAC.00078-20","article-title":"Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model","volume":"64","author":"Bernhard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116993_bib0028","doi-asserted-by":"crossref","first-page":"e00180","DOI":"10.1128\/AAC.00180-20","article-title":"Pharmacodynamics of Cefepime combined with the novel extended-spectrum-\u03b2-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae","volume":"64","author":"Johnson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116993_bib0029","doi-asserted-by":"crossref","first-page":"e01468","DOI":"10.1128\/AAC.01468-20","article-title":"Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia","volume":"65","author":"Das","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325003165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:38:21Z","timestamp":1755553101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325003165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0732889325003165"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116993","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of cefepime\/enmetazobactam against extended spectrum beta-lactamases and\/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116993"}}